Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,187 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER2-normal Clear all

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Metastatic Breast Cancer
Interventions: Pertuzumab, Placebo, Trastuzumab, Docetaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 808 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 159
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • Alhambra, California + 120 more

Conditions: BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma
Interventions: Educational Intervention, Genetic Counseling, Laboratory Biomarker Analysis, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 5,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Metastatic Breast Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions: Enzalutamide, Trastuzumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Breast Cancer
Interventions: Ixabepilone, Cyclophosphamide; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 20
States / cities: Aventura, Florida • Fort Myers, Florida • Lakeland, Florida + 16 more

Conditions: Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more

Conditions: Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Tubular Ductal Breast Carcinoma
Interventions: external beam radiation therapy, questionnaire administration, therapeutic conventional surgery; Radiation · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Cleveland, Ohio • Orange, Ohio • Westlake, Ohio

Conditions: HER-2 Positive Metastatic Breast Cancer
Interventions: Etoposide, Trastuzumab; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 945 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer, ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Interventions: ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Altanta, Georgia • Boston, Massachusetts + 5 more

Conditions: HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy; Other · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 292
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: Camizestrant, Ribociclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Duarte, California • Palo Alto, California • Marietta, Georgia + 9 more

Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions: BNT323, BNT327; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 19 more

Conditions: Breast Cancer, Malignant Neoplasm of Breast
Interventions: Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Afatinib once daily (OD), Vinorelbine Weekly; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Breast Cancer
Interventions: trastuzumab, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 44
States / cities: Palo Alto, California • Stanford, California • Denver, Colorado + 35 more

Conditions: Breast Cancer
Interventions: Trastuzumab; Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions: BG-68501, Fulvestrant, BGB-43395; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: HER-2/neu intracellular domain protein, leukapheresis, laboratory biomarker analysis, sargramostim, immunologic technique, synthetic tumor-associated peptide vaccine therapy; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: letrozole, panobinostat, RNA analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay, immunohistochemistry staining method, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 172
States / cities: Scottsdale, Arizona • Martinez, California • Mountain View, California + 119 more

Conditions: Breast Cancer
Interventions: pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 3,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 539
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more

Conditions: Breast Cancer, Gastric Cancer, Solid Tumors, NSCLC
Interventions: Pyrotinib; Drug
Lead sponsor: Hengrui Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Orange, California • Sacramento, California • Sarasota, Florida + 6 more

Conditions: Recurrent or Metastatic Solid Tumors
Interventions: Ifinatamab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more

Search by objective public record fields.

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)